Search

COVID-19 is an infectious disease caused by the novel coronavirus SARS-CoV-2, which rapidly spreads via respiratory droplets and is the cause of the current pandemic. In this alarming situation, it is a delicate matter how to visit patients safely and how to manage their chronic treatments. The aim of this paper is to examine in detail the potential impact on SARS-CoV-2 infection of treatments routinely used in trichology and to provide a useful guide for the therapeutic management of trichological patients in this new COVID-19 era. [ABSTRACT FROM AUTHOR]

Background: Common COVID‐19 vaccines side effects are pain at the injection site, muscle pain, fever, headaches, fatigue. Possible immune‐related side effects in predisposed individuals have not been established so far. Materials and Methods: We report three cases of recurrence of alopecia areata (AA) occurred after the first dose of COVID‐19 vaccine. Results: All patients had previous episodes of AA with total hair regrowth and stable remission during the months preceding the vaccination. Rapid hair loss occurred 2‐3 weeks after BNT162b2 mRNA (patient 1) and AZD1222/ChAdOx1 vaccine (patient 2 and 3), with widespread hair loss in two cases and a single patch of the vertex in one case, with typical trichoscopic features of AA. Discussion: Both BNT162b2 mRNA and AZD1222/ChAdOx1 vaccines share the same goal of inducing the immune system, with antibodies production and Th1 cells activation with release of pro‐inflammatory cytokines. Thus, in patients with pre‐existing inflammatory dysregulated pathways, the interaction between the immune system and vaccines may enhance other autoimmune mechanisms. In our cases, we speculate that vaccine may have induced the hair loss focusing on components having a key role in both COVID‐19 vaccination and AA pathogenesis. Conclusion: This report may help to collect new data concerning possible immune‐related effects of vaccines. Certainly, only three cases are not sufficient to draw conclusion, thus a large‐scale study is necessary. Immune‐mediated side effects remain a rare event, thus the benefits of COVID‐19 vaccines outweigh the risk of disease flares and we strongly recommend it in all eligible patients with AA. [ABSTRACT FROM AUTHOR]

Keywords: alopecia areata; COVID-19; SARS-CoV-2 EN alopecia areata COVID-19 SARS-CoV-2 2004 2005 2 06/23/21 20210701 NES 210701 Coronavirus disease (COVID-19) has spread across the globe from December 2019 determining the current pandemic. Only two previous cases of new-onset AA after SARS-CoV-2 infection have been described,2,3 and our report is the third published case of new-onset AA in a COVID-19 patient, and the second one with total distribution. Stress is one of the most common trigger exacerbating or inducing AA; thus, cases of AA in individuals with COVID-19 could be a consequence of the psychological distress related to the infection. [Extracted from the article]